These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 15462390)

  • 1. [The therapy of wearing-off].
    Murata M
    Nihon Rinsho; 2004 Sep; 62(9):1716-9. PubMed ID: 15462390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [New therapeutic strategy for Parkinson's disease based on pharmacological profiles].
    Ogawa N
    Nihon Rinsho; 1997 Jan; 55(1):43-51. PubMed ID: 9014422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of advanced Parkinson's disease].
    Momose Y; Murata M; Kanazawa I
    Nihon Rinsho; 2000 Oct; 58(10):2061-5. PubMed ID: 11068447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: implications for the early use of COMT inhibitors.
    Olanow CW; Obeso JA
    Neurology; 2000; 55(11 Suppl 4):S72-7; discussion S78-81. PubMed ID: 11147513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment strategies for extension of levodopa effect.
    LeWitt PA
    Neurol Clin; 1992 May; 10(2):511-26. PubMed ID: 1584187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease.
    Fabbrini G; Juncos J; Mouradian MM; Serrati C; Chase TN
    Ann Neurol; 1987 Apr; 21(4):370-6. PubMed ID: 3579222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ropinirole therapy for Parkinson's disease.
    Pahwa R; Lyons KE; Hauser RA
    Expert Rev Neurother; 2004 Jul; 4(4):581-8. PubMed ID: 15853577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The new Parkinson's disease drugs].
    Hasegawa K
    Nihon Rinsho; 2000 Oct; 58(10):2066-71. PubMed ID: 11068448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms.
    Bravi D; Mouradian MM; Roberts JW; Davis TL; Sohn YH; Chase TN
    Ann Neurol; 1994 Jul; 36(1):27-31. PubMed ID: 8024257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Initial treatment of Parkinson's disease].
    Kulisevsky J; López-Villegas D
    Rev Neurol; 1997 Aug; 25 Suppl 2():S163-9. PubMed ID: 9280684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease.
    Olanow CW; Obeso JA; Stocchi F
    Nat Clin Pract Neurol; 2006 Jul; 2(7):382-92. PubMed ID: 16932589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Problems of long-term levodopa therapy in Parkinson's disease].
    Nakamura Y
    Nihon Rinsho; 1997 Jan; 55(1):65-71. PubMed ID: 9014425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of levodopa failures: the use of dopamine agonists.
    Lieberman AN; Gopinathan G; Neophytides A; Goldstein M
    Clin Neuropharmacol; 1986; 9 Suppl 2():S9-21. PubMed ID: 3297319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of motor complications in advanced Parkinson's disease.
    Melamed E; Ziv I; Djaldetti R
    Mov Disord; 2007 Sep; 22 Suppl 17():S379-84. PubMed ID: 18175400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bromocriptine in Parkinson disease.
    Lieberman AN; Goldstein M
    Pharmacol Rev; 1985 Jun; 37(2):217-27. PubMed ID: 3901046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Wearing-off phenomenon--neurological approach].
    Ishikawa A
    Nihon Rinsho; 2000 Oct; 58(10):2100-3. PubMed ID: 11068454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Drug therapy of patients with early-stage parkinson's disease].
    Kondo T
    Nihon Rinsho; 2000 Oct; 58(10):2055-60. PubMed ID: 11068446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuous dopaminergic stimulation and novel formulations of dopamine agonists.
    Stocchi F
    J Neurol; 2011 May; 258(Suppl 2):S316-22. PubMed ID: 21560062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of monoamine oxidase B (MAOB) and catechol-O-methyltransferase (COMT) polymorphisms on levodopa therapy in patients with sporadic Parkinson's disease.
    Białecka M; Droździk M; Kłodowska-Duda G; Honczarenko K; Gawrońska-Szklarz B; Opala G; Stankiewicz J
    Acta Neurol Scand; 2004 Oct; 110(4):260-6. PubMed ID: 15355491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.